Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Multiomic Single Cell Profiling Identifies Drivers of Progression in T-Cell Prolymphocytic Leukemia

Vishakha Anand Pawar, Arnau Peris Cuesta, Akanksha Aradhya, Claudia Kettlun, Swaminathan P Iyer, Sachet Shukla, Tapan M. Kadia, Francisco Vega, Deepa Sampath

Blood (2024) 144 (Supplement 1): 6230.

https://doi.org/10.1182/blood-2024-208729

Published: 2024

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Hun Ju Lee, Gregory Ravizzini, Eslam Aboismail, Jenna Wixom, Jared Henderson, Luis E. Fayad, Sairah Ahmed, Ranjit Nair, Jason R. Westin, Swaminathan P Iyer, Chijioke Nze, Ajlan Al Zaki, Francisco Vega, Michael Wang, Christopher R. Flowers, Luis Malpica

Blood (2024) 144 (Supplement 1): 1674.3.

https://doi.org/10.1182/blood-2024-212005

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Swaminathan P Iyer, Ranjit Nair, Neha Mehta-Shah, Don A. Stevens, Alessandra Tucci, Antonio Pinto, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4449.

https://doi.org/10.1182/blood-2024-209340

Published: 2024

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood (2024) 144 (Supplement 1): 805.

https://doi.org/10.1182/blood-2024-204230

Published: 2024

Journal Articles

Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data

Alexandra Elias, Rishab Prakash, Ranjit Nair, Luis Malpica, Hun Ju Lee, Eguono Maples, Samantha Carlson, Luis E. Fayad, Krina K. Patel, Sairah Ahmed, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 611.

https://doi.org/10.1182/blood-2024-212332

Published: 2024

Journal Articles

Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

Kunhwa Kim, Auris O Huen, Julia Dai, Rishabh Lohray, Bouthaina S. Dabaja, Jillian R. Gunther, Susan Y. Wu, Carlos P Torres-Cabala, Ranjit Nair, Luis Malpica, Yago Nieto, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 7448.

https://doi.org/10.1182/blood-2024-212007

Published: 2024

Journal Articles

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Blood (2024) 144 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2024-209213

Published: 2024

Journal Articles

Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL

Carolina Romero, Macarena Roa, Henry Idrobo, Denisse Castro, Brady E Beltran, Daniel J Enriquez, Jule F Vasquez, Claudia Roche, Daniel Artiles, Fabiola Valvert, Luis Mario Villela Martinez, Juliana Pereira, Ana Carolina Oliver, Jamila Vaz Tavarez, Sergio Augusto B Brasil, Karin Z Cecyn, Nelson S Castro, Renata Lyrio R Baptista, Samuel S. Medina, Davimar Miranda Maciel Borducchi, Marcelo Bellesso, Danielle Leão Cordeiro De Farias, Yung Gonzaga, Laura Korin, Patricio Pereyra, Camila Peña, Maria Alejandra Torres Viera, Kelly Meza, Seisha Von Glasenapp, Alfredo Quiroz, Cesar Samanez-Figari, Rosa Oliday Rios Jimenez, Sally Paredes, Thais Fischer, Asaad Trabolsi, Jonathan H. Schatz, Swaminathan P Iyer, Ranjit Nair, Eduardo Edelman Saul, Casey Bermack, Jorge J. Castillo, Carmino De Souza, Eliana Miranda, Bryan Valcarcel, Carlos Chiattone, Luis Enrique Malpica Castillo

Blood (2024) 144 (Supplement 1): 983.

https://doi.org/10.1182/blood-2024-205295

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study

Juan Esteban Garcia-Robledo, Henry Quintero, Denisse Castro, Brady E Beltran, Daniel J Enriquez, Jule F Vasquez, Claudia Roche, Daniel Artiles, Fabiola Valvert, Luis Mario Villela Martinez, Juliana Pereira, Ana Carolina Oliver, Jamila Vaz Tavarez, Sergio Augusto B Brasil, Karin Z Cecyn, Nelson S Castro, Renata Lyrio R Baptista, Samuel S. Medina, Davimar Miranda Maciel Borducchi, Marcelo Bellesso, Danielle Leão Cordeiro De Farias, Yung Gonzaga, Laura Korin, Patricio Pereyra, Camila Peña, Macarena Roa, Maria Alejandra Torres Viera, Kelly Meza, Seisha Von Glasenapp, Alfredo Quiroz, Cesar Samanez-Figari, Rosa Oliday Rios Jimenez, Sally Paredes, Thais Fischer, Asaad Trabolsi, Jonathan H. Schatz, Swaminathan P Iyer, Ranjit Nair, Eduardo Edelman Saul, Casey Bermack, Jorge J. Castillo, Carmino De Souza, Eliana Miranda, Bryan Valcarcel, Carlos Chiattone, Luis Enrique Malpica Castillo

Blood (2024) 144 (Supplement 1): 1687.

https://doi.org/10.1182/blood-2024-205881

Published: 2024

Journal Articles

Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center

Rishab Prakash, James Long, Benjamin Mescher, Paul Edelkamp, Jr., Mark Knafl, Jeff Jin, Trey Kell, Naveen Garg, Ajlan Al Zaki, Dai Chihara, Luis Malpica, Ranjit Nair, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2024-211892

Published: 2024

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

Casey Bermack, Ke Pan, Yulun Chiu, Luis Malpica, Swaminathan P Iyer, Christopher R. Flowers, Cassian Yee

Blood (2024) 144 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2024-207926

Published: 2024

Journal Articles

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Blood (2024) 144 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2024-207616

Published: 2024

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

Newer insights on how to TEC down T-ALL

Swaminathan P. Iyer

Blood (2023) 141 (5): 444–445.

https://doi.org/10.1182/blood.2022018004

Published: 2023

NARROW

Multiomic Single Cell Profiling Identifies Drivers of Progression in T-Cell Prolymphocytic Leukemia

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data

Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study

Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Newer insights on how to TEC down T-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only